Results 201 to 210 of about 36,394,742 (371)

Factor H-related proteins determine complement-activating surfaces.

Trends in immunology, 2015
M. Józsi, A. Tortajada, B. Uzonyi, E. Goicoechea de Jorge, S. Rodríguez de Córdoba   +4 more
semanticscholar   +1 more source

Serum Complement Factor H: A Marker for Progression and Outcome Prediction Towards Immunotherapy in Cutaneous Squamous Cell Carcinoma. [PDF]

Cancers (Basel)
Geidel G, Adam L, Bänsch S, Fekade N, Deitert B, Rünger A, Kött J, Zell T, Heidrich I, Smit DJ, Pantel K, Schneider SW, Gebhardt C.   +12 more
europepmc   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

The Sialome of the Retina, Alteration in Age-Related Macular Degeneration Pathology, and Potential Impacts on Complement Factor H. [PDF]

Invest Ophthalmol Vis Sci
Swan J, Toomey CB, Bergstrand M, Cuello HA, Robie J, Yu H, Yuan Y, Kooner AS, Chen X, Shaughnessy J, Ram S, Varki A, Gagneux P.   +12 more
europepmc   +1 more source

Two separate genes regulate self-Ia and carrier recognition in H-2-restricted helper factors secreted by hybridoma cells. [PDF]

, 1981
Peter Lonai, S Bitton, H.F.J. Savelkoul, Joseph Puri, Günter J. Hämmerling   +4 more
openalex   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment. [PDF]

Cancer Immunol Res
Smolag KI, Olszowka J, Rosberg R, Johansson E, Marinko E, Leandersson K, O'Connell DJ, Governa V, Tuysuz EC, Belting M, Pietras A, Martin M, Blom AM.   +12 more
europepmc   +1 more source

The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. [PDF]

, 1983
E.J. Brown, Keith A. Joiner, T A Gaither, Carl H. Hammer, Martin Frank   +4 more
openalex   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

Kidney International, 2014
A. Sinha, A. Gulati, S. Saini, C. Blanc, Aarti Gupta, B. Gurjar, Himanshi Saini, Shambhuprasad T Kotresh, U. Ali, D. Bhatia, A. Ohri, Manish Kumar, I. Agarwal, S. Gulati, K. Anand, M. Vijayakumar, R. Sinha, S. Sethi, M. Salmona, A. George, V. Bal, Geetika Singh, A. Dinda, P. Hari, S. Rath, M. Dragon-Durey, A. Bagga   +26 more
semanticscholar   +1 more source